My major research interests are the pathogenesis and management of viral-associated malignancies, including cancers that occur in the setting of HIV. I have specific training in clinical investigation and more than 10 years of clinical trial experience focusing on herpesvirus and related malignancies. My research also explores novel biomarkers in KSHV-associated diseases and HIV viral reservoirs in the setting of cancer. Active projects include: (1) Evaluation of the natural history of KSHV-associated disorders, including Kaposi sarcoma (KS), KSHV-associated multicentric Castleman disease, primary effusion lymphoma, and a novel entity we described, KSHV-associated Inflammatory Cytokine Syndrome (KICS), (2) Early-phase treatment studies in KSHV-associated malignancies employing immune modulating therapies and (3) Evaluation the safety and efficacy of anti-PD-1 therapy in patients with HIV and cancer, which includes evaluation of the effect of anti-PD-1 therapy on HIV reservoirs and HIV-specific immunity. This last study is a multicenter study developed in collaboration with the Cancer Immunotherapy Trials Network and the Delaney AIDS Research Enterprise to Cure HIV. I have a strong interest in disease pathogenesis and development of novel strategies for diagnosis and management of cancers in resource limited settings. This is my focus of research as the Deputy Head of Global Oncology, where I collaborate with investigators in Uganda and South Africa on patient-oriented research projects.